quinuclidines has been researched along with fosaprepitant in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Balu, S; Buchner, D; Jackson, J; Jain, G; Schwartzberg, L | 1 |
| Basch, E; Chesney, M; Clark-Snow, RA; Feyer, PC; Flaherty, AM; Freundlich, B; Hesketh, PJ; Kris, MG; Lyman, GH; Morrow, G; Prestrud, AA; Rao, KV; Schwartz, RN; Somerfield, MR | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Endo, M; Katsube, Y; Motohashi, R; Nakamura, K; Sato, H; Suzuki, M; Tsukahara, K; Ueda, Y | 1 |
| Doi, A; Hirayama, M; Kitayama, H; Kondo, T; Sugiyama, J; Tsuji, Y | 1 |
| Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E | 1 |
| Herrstedt, J; Ruhlmann, CH | 1 |
| Akiyoshi, K; Hata, A; Inui, N; Kubota, K; Morise, M; Okada, M; Okamoto, I; Saeki, T; Shinagawa, N; Sugawara, S; Takeda, M; Tamura, T; Watanabe, Y | 1 |
2 review(s) available for quinuclidines and fosaprepitant
| Article | Year |
|---|---|
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Serotonin Antagonists; Surveys and Questionnaires; Vomiting | 2011 |
New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Vomiting | 2016 |
4 trial(s) available for quinuclidines and fosaprepitant
| Article | Year |
|---|---|
Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma; Cisplatin; Dexamethasone; Drug Therapy, Combination; Eating; Female; Head and Neck Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Serotonin Antagonists | 2014 |
Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Preference; Prospective Studies; Quinuclidines; Single-Blind Method; Treatment Outcome; Vomiting | 2015 |
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Time Factors; Treatment Outcome; Vomiting | 2022 |
2 other study(ies) available for quinuclidines and fosaprepitant
| Article | Year |
|---|---|
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Aprepitant; Databases, Factual; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |